Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

OBJECTIVES: We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment. METHODS: Retrospective review (May 2014 – December 2016) of VICTORY Consortium data. Adults with follow-up after starting VDZ for clinically activ...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am J Gastroenterol
Главные авторы: Narula, Neeraj, Peerani, Farhad, Meserve, Joseph, Kochhar, Gursimran, Chaudrey, Khadija, Hartke, Justin, Chilukuri, Prianka, Koliani-Pace, Jenna, Winters, Adam, Katta, Leah, Shmidt, Eugenia, Hirten, Robert, Faleck, David, Parikh, Malav P., Whitehead, Diana, Boland, Brigid S., Singh, Siddharth, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Barocas, Morris, Luo, Michelle, Lasch, Karen, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Siegel, Corey A., Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Dulai, Parambir S.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445254/
https://ncbi.nlm.nih.gov/pubmed/29946178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41395-018-0162-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы